Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193736 | 0.85 | IDO1 (0.44) | MAPTHTTHSP90AA1HPGDHSD17B10 | |
| SCHEMBL1295362 | 0.77 | MAPT (0.35) | MAPTHTTHSP90AA1HSD17B10LMNA | |
| SCHEMBL30873742 | 0.75 | MAPT (0.46) | MAPTHTTHSP90AA1RECQLTHRB | |
| SCHEMBL5800459 | 0.75 | CYP1A2 (0.48) | MAPTHTTHSP90AA1HPGDHSD17B10 | |
| SCHEMBL1747611 | 0.75 | MAPT (0.46) | MAPTHTTHSP90AA1RECQLTHRB | |
| SCHEMBL1261956 | 0.75 | ALDH1A1 (0.48) | MAPTHTTHSP90AA1HPGDHSD17B10 | |
| SCHEMBL12751165 | 0.75 | MAPT (0.34) | MAPTHTTHSP90AA1LMNAKDM4E | |
| SCHEMBL2798258 | 0.75 | CYP1A2 (0.48) | MAPTHTTHSP90AA1CYP1A2ALDH1A1 | |
| SCHEMBL9332720 | 0.75 | MAPT (0.51) | MAPTHTTHPGDHSD17B10ALOX15 | |
| SCHEMBL9332711 | 0.75 | HPGD (0.41) | MAPTHTTHPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060105410-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | claimed |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | claimed |
| EP-1650200-A1 | SULFONATE COMPOUND AND FLUORESCENT PROBE USING THE SAME | Osaka Industrial Promotion Organization (JP) | 2006-04-26 | — | — | EP | claimed |
| CN-109776412-B | Synthesis method of N oxide | 陕西大生制药科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-7491832-B2 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7465814-B2 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1499319-B1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20060105410-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-7037913-B2 | Piperazinyl derivatives of naphthalenes, (iso)quinolines and naphthyridines; used particularly the treatment of HIV and AIDS. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1650200-A1 | SULFONATE COMPOUND AND FLUORESCENT PROBE USING THE SAME | Osaka Industrial Promotion Organization (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-1499319-A4 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1499319-A1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040009985-A1 | Bicyclo 4.4.0 antiviral derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003092695-A1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105410-A1 | Sulfonate compound and fluorescent probe using the same | BRS3, NCOA3, NR4A3 | MAPT 4674/4885HTT 3932/4885HSP90AA1 4737/4885 |
| US-20040009985-A1 | Bicyclo 4.4.0 antiviral derivatives | CCR5, ITPA, IL4 | MAPT 3383/4885HTT 4301/4885HSP90AA1 3916/4885 |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | SLCO1B3, CBR3, SLCO2B1 | MAPT 4468/4885HTT 3866/4885HSP90AA1 4565/4885 |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | MAPT 4152/4885HTT 1005/4885HSP90AA1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.